MT Newswires
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gain 4% for Week
📊
AI Sentiment
Positive
6/10
- Home
- AKTX
as of 12-02-2025 4:00pm EST
$0.35
$0.06
-14.10%
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Chart Type:
Time Range:
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | TAMPA |
| Market Cap: | 17.2M | IPO Year: | N/A |
| Target Price: | $3.30 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.32 - $1.73 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered AKTX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 74.48%
74.48%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Akari Therapeutics plc ADS News
AKTX Breaking Stock News: Dive into AKTX Ticker-Specific Updates for Smart Investing
MT Newswires
European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
📊
AI Sentiment
Positive
7/10
GlobeNewswire
Akari Therapeutics Announces Release of the Next CEO Corner Segment
📊
AI Sentiment
Positive
7/10
Compare AKTX vs Leading Stocks
See how AKTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AKTX Akari Therapeutics plc ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.